BMS-741672 

BMS-741672 is a selective and orally active CCR2 antagonist with an IC₅₀ of 1.1 nM. BMS-741672 shows >700-fold selective for CCR2 than CCR5^[1].

BMS-741672 exhibitsan IC₅₀ of 0.67 nM for the inhibition of monocyte chemotaxis in vitro and was fully active in both monkey and hCCR2 knock-in mouse models of monocyte chemotaxis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

BMS-741672 is found to have 51% oral bioavailability in a rat with a t_1/2 value of 5.1 h (IV), and there is 46% oral bioavailability in a cynomolgus monkey with a t_1/2 of 3.2 h (IV)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

506.56

C₂₅H₃₃F₃N₆O₂

1004757-96-3

CC(N[C@H]1[C@@H](N2C([C@H](CC2)NC3=NC=NC4=C3C=C(C(F)(F)F)C=C4)=O)CC[C@H](C1)N(C)C(C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Michael G Yang, et al. Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672. ACS Med Chem Lett. 2019 Jan 16;10(3):300-305.  [Content Brief]